Modified Bombesin Peptide Enables Cancer Imaging with Minimal Pancreas Uptake — a Long-Standing Problem Solved
Replacing a single amino acid (Thz14→Pro14) in bombesin-based peptide tracers produced a GRPR antagonist ([68Ga]Ga-ProBOMB5) with strong tumor uptake (12.4%ID/g) and minimal pancreas accumulation (0.60-1.37%ID/g) — solving a critical safety issue for clinical translation.
Quick Facts
What This Study Found
The bombesin peptide modification Thz14→Pro14 produced [68Ga]Ga-ProBOMB5 with high tumor uptake (12.4±1.35%ID/g), strong binding affinity (Ki: 12.2 nM), and minimal pancreas accumulation (0.60-1.37%ID/g) — a major improvement over existing GRPR tracers.
Key Numbers
One antagonist (ProBOMB5) and two agonists (LW02056, LW02057) synthesized; labeled with 68Ga and 177Lu; Pro14 substitution replacing Thz14 residue.
How They Did This
Synthesized three [Pro14]bombesin(8-14) derivatives (one antagonist, two agonists). Performed 68Ga and 177Lu radiolabeling, in vitro binding affinity assays (Ki), PET imaging and biodistribution in PC-3 tumor-bearing mice at 1h post-injection, and longitudinal SPECT imaging comparing [177Lu]Lu-ProBOMB5 with [177Lu]Lu-RM2.
Why This Research Matters
GRPR-targeted imaging could transform prostate cancer diagnosis and treatment monitoring, but high pancreas radiation has been a deal-breaker for most tracers. ProBOMB5's minimal pancreas uptake removes this barrier, potentially enabling safe, routine use of GRPR PET imaging to detect and monitor cancers that express this receptor.
The Bigger Picture
This work directly addresses the biggest obstacle to clinical adoption of GRPR-targeted radiopharmaceuticals. With minimal pancreas uptake solved, ProBOMB5 joins a growing arsenal of peptide-based cancer imaging agents alongside PSMA-targeted tracers. For patients whose cancers express GRPR but not PSMA, this could be the PET tracer that enables precision diagnosis and treatment planning.
What This Study Doesn't Tell Us
Mouse study — human biodistribution may differ. The therapeutic lutetium-177 version showed faster tumor clearance than RM2, limiting its radiation dose to tumors for therapy. Only one tumor model (PC-3) tested. Clinical trials needed to confirm the favorable pancreas profile in humans.
Questions This Raises
- ?Can the [177Lu]Lu-ProBOMB5 structure be further modified to slow tumor clearance and improve its therapeutic potential?
- ?Does the favorable pancreas profile hold in humans, where GRPR expression patterns may differ from mice?
- ?Could ProBOMB5 be combined with PSMA-targeted tracers for comprehensive prostate cancer imaging?
Trust & Context
- Key Stat:
- Pancreas uptake: 0.60-1.37%ID/g vs. typically >10%ID/g for other GRPR tracers — a dramatic reduction that removes the major safety barrier to clinical use, while maintaining tumor uptake of 12.4%ID/g
- Evidence Grade:
- Preliminary — preclinical proof-of-concept with promising PET imaging data in a single mouse tumor model. Clinical translation appears feasible for the imaging application but needs human trials.
- Study Age:
- Published in 2024, advancing GRPR-targeted radiopharmaceutical development toward clinical readiness.
- Original Title:
- Synthesis and Evaluation of 68Ga- and 177Lu-Labeled [Pro14]bombesin(8-14) Derivatives for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer.
- Published In:
- Molecular pharmaceutics, 21(12), 6385-6397 (2024)
- Authors:
- Wang, Lei(12), Kuo, Hsiou-Ting, Chapple, Devon E, Chen, Chao-Cheng, Kurkowska, Sara, Colpo, Nadine, Uribe, Carlos, Bénard, François, Lin, Kuo-Shyan
- Database ID:
- RPEP-09478
Evidence Hierarchy
Frequently Asked Questions
Why is pancreas accumulation such a big problem for cancer imaging tracers?
The pancreas normally expresses GRPR, so most GRPR-targeted tracers accumulate heavily there, delivering unwanted radiation to a sensitive organ. This limits how much tracer can be safely injected and can make the pancreas 'light up' on scans, potentially obscuring nearby tumors. ProBOMB5's minimal pancreas uptake means patients can receive the tracer safely while getting clear images of their tumors.
What cancers could this tracer help detect?
GRPR is overexpressed in prostate cancer, breast cancer, lung cancer, and several other tumor types. ProBOMB5 could help detect and monitor any GRPR-expressing cancer. It may be especially valuable for prostate cancers that don't express PSMA (the most common imaging target), providing an alternative pathway for diagnosis and treatment planning.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09478APA
Wang, Lei; Kuo, Hsiou-Ting; Chapple, Devon E; Chen, Chao-Cheng; Kurkowska, Sara; Colpo, Nadine; Uribe, Carlos; Bénard, François; Lin, Kuo-Shyan. (2024). Synthesis and Evaluation of 68Ga- and 177Lu-Labeled [Pro14]bombesin(8-14) Derivatives for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer.. Molecular pharmaceutics, 21(12), 6385-6397. https://doi.org/10.1021/acs.molpharmaceut.4c00952
MLA
Wang, Lei, et al. "Synthesis and Evaluation of 68Ga- and 177Lu-Labeled [Pro14]bombesin(8-14) Derivatives for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer.." Molecular pharmaceutics, 2024. https://doi.org/10.1021/acs.molpharmaceut.4c00952
RethinkPeptides
RethinkPeptides Research Database. "Synthesis and Evaluation of 68Ga- and 177Lu-Labeled [Pro14]b..." RPEP-09478. Retrieved from https://rethinkpeptides.com/research/wang-2024-synthesis-and-evaluation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.